Strategic Signals Weekly

Gossamer Bio, Inc. secured a private placement agreement to raise up to $250 million, with an initial $25.0 million closing. Additional funds of $125.0 million are contingent on FDA acceptance of the NDA for seralutinib in pulmonary arterial hypertension (PAH) by 2026, and a further $100.0 million from warrants upon FDA approval. Proceeds will support the clinical development and potential commercialization of seralutinib for PAH and PH-ILD.

Drug: seralutinib · Indication: pulmonary arterial hypertension

Genprex, Inc. announced a strategic development and manufacturing agreement with a leading U.S. based CDMO to scale up production of its diabetes gene therapy program. This collaboration will transition the AAV-based therapeutic candidate, designed for Type 1 and Type 2 diabetes, from research-grade to cGMP-compliant clinical and commercial-ready output. The CDMO will supply drug product for IND-enabling preclinical studies and future clinical trials.

Werewolf Therapeutics, Inc. entered into an asset purchase agreement with EMD Serono Research & Development Institute Inc. (EMD), selling its pre-clinical INDUCER and INDUKINE platforms for an upfront consideration of $28.0 million, plus an additional $5.0 million upon technology transfer. Werewolf retained rights to its WTX-124 and WTX-330 clinical programs and simultaneously entered into a license agreement with EMD, granting Werewolf an exclusive license to certain patents from the transferred assets to continue developing WTX-124 and WTX-330.

Drug: WTX-124, WTX-330 · Partner: EMD Serono Research & Development Institute Inc.

Kiora Pharmaceuticals, Inc. entered into an exclusive license and development agreement with Chong Jun Dang Pharmaceutical Corporation (CKD) for its KIO-301 molecular photoswitch product in South Korea. Under the agreement, CKD gains exclusive rights to develop, manufacture, and commercialize KIO-301 for retinitis pigmentosa and other ophthalmology indications in the territory, and will coordinate efforts for a global Phase 3 clinical trial. Kiora received an upfront payment of $1.0 million and is eligible for additional milestone payments and double-digit royalties on net sales.

Drug: KIO-301 · Indication: retinitis pigmentosa · Partner: Chong Jun Dang Pharmaceutical Corporation

Amgen Inc. has elected to terminate its Research Collaboration and License Agreement with TScan Therapeutics, Inc., effective November 10, 2026, following a 90-day notice. The collaboration, established in May 2023, focused on identifying T-cell antigens for Crohn's disease and included a $30 million upfront payment to TScan. TScan will wind down its activities and does not anticipate future milestone or royalty payments unless Amgen continues to exploit product candidates.

Indication: Crohn's disease · Partner: Amgen Inc.

Coherus Oncology, Inc. announced a special dividend of contingent value rights (CVRs) to stockholders, effective September 30, 2026. These CVRs provide holders with potential cash payments from the future sale, licensing, or disposition of the company's "Legacy BioSim Assets," which encompass patents, existing license royalties, cell lines, and related materials. The CVR payment term runs from October 7, 2026, to October 7, 2028, with an investment bank engaged to assist in the sale process for these assets.

Gossamer Bio, Inc. secured a private placement agreement to raise up to $250 million, with an initial $25.0 million closing. Additional funds of $125.0 million are contingent on FDA acceptance of the NDA for seralutinib in pulmonary arterial hypertension (PAH) by 2026, and a further $100.0 million from warrants upon FDA approval. Proceeds will support the clinical development and potential commercialization of seralutinib for PAH and PH-ILD.

Werewolf Therapeutics, Inc. entered into a merger agreement with Ambros Therapeutics, Inc., under which Ambros stockholders are expected to own approximately 71.7% of the combined company. Concurrently, Werewolf is conducting a $100.0 million private placement (PIPE financing), with participating investors anticipated to own about 21.5% of the combined entity. The merger and financing are subject to customary closing conditions, including stockholder approvals.

Universal Health Services, Inc. completed a public offering of $1.1 billion in senior secured notes on August 20, 2026. This includes $600 million of 5.500% Senior Secured Notes due 2031 and $500 million of 6.000% Senior Secured Notes due 2036. The notes are guaranteed by the Issuer's subsidiaries and secured by first-priority liens on certain assets, ranking equally with existing senior secured obligations.

MannKind Corporation filed a prospectus supplement to its automatic shelf registration statement on Form S-3, relating to the potential issuance and sale of common stock. This 8-K filing specifically includes the legal opinion from Cooley LLP concerning the legality of these shares.

CalciMedica, Inc. stockholders approved the issuance of equity, including Series A and Series B Warrants, to certain investors as part of a private placement under a Securities Purchase Agreement dated June 23, 2026. This approval, required by Nasdaq Listing Rules, also covered the issuance of shares upon exercise of these warrants. Additionally, stockholders approved a reverse stock split and an increase in shares authorized under the 2023 Equity Incentive Plan.